top of page

Watch Professor Darren Hargrave Discuss Groundbreaking GD2-CAR T Cell Therapy for DIPG/DMG

We are thrilled to share an exciting development in the fight against Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG). In a groundbreaking clinical trial, 12 children in the UK will be the first to access GD2-CAR T Cell Therapy for these devastating brain cancers. This innovative treatment approach has shown promise in similar studies at Stanford University in the US and is now being brought to the UK thanks to a significant £1.2 million grant awarded to University College London (UCL) and Great Ormond Street Hospital (GOSH).



The Role of Abbie’s Army and Collaborating Charities


Abbie’s Army is proud to have played a crucial role in funding this pioneering trial. Through our collaborative grant of £275,000 to the GOSH Children’s Charity, and with additional support from The Azaylia Foundation and CRIS Cancer Foundation, we are helping to pave the way for this groundbreaking treatment. We are also grateful for the support of six other parent-led charities: Islastones Foundation, Bradley Lowery Foundation (including Kaleigh’s Trust and The Spider Ede Appeal - DIPG Awareness), Robert Andrew Munro Foundation, Eva’s Angels, Doing It For Daniel, and Edie’s Kindness Project. Together, we are working towards a future where DIPG and DMG are no longer a devastating diagnosis.



Watch and Learn: Professor Darren Hargrave’s Insight


To understand the impact of this trial and the science behind GD2-CAR T Cell Therapy, we encourage you to watch a compelling video featuring Professor Darren Hargrave, GOSH Charity Clinical Professor in Paediatric Neuro-Oncology and Honorary Consultant at GOSH. In the video, Professor Hargrave explains the latest advancements in this clinical trial, the mechanism of CAR T-cell therapy, and the potential it holds for transforming treatment outcomes for children with DIPG/DMG.





Why Your Support Matters


This clinical trial represents a beacon of hope for children battling DIPG and DMG. However, to continue advancing research and to bring innovative treatments like GD2-CAR T Cell Therapy to more children, we need your support. Funding for research is essential in developing new treatments and improving outcomes for these young patients.



Call to Action


Your contribution can make a significant impact. We invite you to support Abbie’s Army and our mission by donating to fund more groundbreaking research like the GD2-CAR T Cell Therapy trial. Every donation helps us continue our vital work and supports the ongoing search for effective treatments and cures.


Donate today and support research efforts. Together, we can bring hope and new possibilities to children facing DIPG and DMG.



Comments


Commenting has been turned off.
bottom of page